tradingkey.logo

LakeShore Biopharma Co Ltd

LSB

0.720USD

-0.010-1.37%
Market hours ETQuotes delayed by 15 min
13.74MMarket Cap
--P/E TTM
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2024H2
FY2024H1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
---149.40M
---145.83M
Net income from continuing operations
---258.94M
---174.52M
Operating gains losses
--102.49M
--19.93M
Deferred tax
---20.91M
---820.35K
Other non-cash items
--59.51M
--18.47M
Change in working capital
---43.75M
---2.04M
-Change in receivables
---14.44M
--28.34M
-Change in inventory
---48.14M
---38.12M
-Change in prepaid expenses
--17.15M
---22.44M
-Change in other current liabilities
---2.46M
---1.15M
Cash from non-recurring investing activities
Cash from operating activities
---149.40M
---145.83M
Investing cash flow
Net cash from continuing investing activities
--20.83M
--23.42M
Capital expenditures
--20.83M
--23.58M
Net cash flow from disposal of fixed assets
--20.83M
--23.42M
Net cash flow from intangible asset transactions
--0.00
--0.00
Cash from non-current investing activities
Net cash flow from investing activities
---20.83M
---23.42M
Financing cash flow
Cash flow from continuous financing activities
--160.41M
--44.86M
Net cash flow from debt Issuance/repayment
---123.79M
--44.86M
Net cash flow from common stock issuance/repurchase
--284.20M
----
Net cash from non-recurrent financing activities
Net cash from financing activities
--160.41M
--44.86M
Net cash flow
Beginning cash balance
--259.91M
--370.37M
Current period cash flow changes
---13.35M
---110.46M
Effect of exchange rate changes
---3.53M
--13.93M
Ending cash balance
--246.55M
--259.91M
Free cash flow
---170.23M
---169.41M
Currency unit
USD
USD
Audit opinions
--
--
KeyAI